HDFC Pharma & Healthcare IDCW Reinvest Direct Plan
SIP amount
Min. ₹100
Lumpsum amount
Min. ₹100

HDFC Pharma & Healthcare IDCW Reinvest Direct Plan

NAV
₹16.2090
-1.13%
(18 Sep)
AUM
1,170 Cr
TER
1.01%
Risk
Very High Risk
Insights
Asset Under Management (AUM) is in the top 25% of comparable funds
In beta. Send feedback here.
Compare with other fund
1Y
+65.2%
+65.2%
+65.2%
+64.4%
NA
3Y
+38.8%
+38.8%
+38.8%
+38.6%
NA
5Y
+29.1%
+29.1%
+29.1%
NA
NA
ALL
+13.2%
+13.2%
+13.2%
+32.6%
+64.5%
VOL
20.3%
20.3%
20.3%
23.2%
11.6%
TER
0.7%
0.7%
0.7%
0.4%
1.0%
AUM
₹4,851 Cr
₹4,851 Cr
₹4,851 Cr
₹5,946 Cr
₹1,170 Cr
INFO
0.65
0.65
0.65
1.41
5.55
Past performance
Past performance is no guarantee of future returns.
Had you invested
Over the last
1Y
3Y
ALL
Your returns would have been
HDFC Pharma & Healthcare IDCW Reinvest (DR)
₹1,00,00,00,000
14.0%
Fixed deposit
₹40,00,00,000
6.0%
Bank savings
₹40,00,00,000
3.0%
See fund holdings as of 31st Aug
Top holdings
Sun Pharmaceuticals Industries Ltd
11.6%
Divi's Laboratories Ltd
7.6%
Cipla Ltd
5.5%
Dr Reddy's Laboratories Ltd
5.4%
Lupin Ltd
4.8%
Aurobindo Pharma Ltd
4.6%
Ajanta Pharma Ltd
3.9%
Gland Pharma Ltd
3.8%
Krishna Institute of Medical Sciences Ltd
3.6%
Ipca Laboratories Ltd
3.3%
Top industry exposure
Healthcare
96.2%
Basic Materials
1.5%
Other information
Minimum SIP
₹100
Minimum lumpsum
₹100
Additional lumpsum
₹100
Portfolio turnover
-
Lock-in period
-
Exit load
• 1% for redemption within 30 days
Fund objective
To provide long-term capital appreciation by investing predominantly in equity and equity related securities of Pharma and healthcare companies. There is no assurance that the investment objective of the Scheme will be realized.
Fund manager(s)
Dhruv Muchhal
Nikhil Mathur

FAQs